MiRACULOUS stands for “MicroRNA-based Innovative Formulations for the Regulation And Control of Oncological Unhealing Sores”; it represents a leap forward in merging cutting-edge science with heartfelt empathy. The project’s focus is to develop therapies that deliver healing microRNAs directly to the wounds of oncology patients, striving to improve their quality of life. In Collaboration with Theramir LTD, who’s proprietary technologies are based on microRNAs (miRNAs), a class of small non-coding RNAs that can regulate multiple genes and pathways associated with cancer growth and metastasis. The company has developed a panel of miRNAs, both biological and synthetic, which can affect the function and disrupt expression of an expanding list of oncoproteins that are dysregulated in most cancer types. Thus, the technologies can be applied to the development of novel targeted therapeutics that may potentially transform the precision oncology field by creating new knowledge on the pathology of the disease and by enabling the customization and personalization of cancer treatment.
*The project is funded By the European Structural & Investment Funds (ESIF) and the Republic of Cyprus through the Research and Innovation Foundation (RIF) under theENTERPRISES/0223/Sub-Call1/